Select Publications

Amado RG et al. Panitumumab (pmab) efficacy and patient-reported outcomes (PRO) in metastatic colorectal cancer (mCRC) patients (pts) with wild-type (WT) KRAS tumor status. Gastrointestinal Cancers Symposium 2008; Abstract 278.

Hecht JR et al. An updated analysis of safety and efficacy of oxaliplatin (Ox)/bevacizumab (bev) +/- panitumumab (pmab) for first-line treatment (tx) of metastatic colorectal cancer (mCRC) from a randomized, controlled trial (PACCE). Gastrointestinal Cancers Symposium 2008a;Abstract 273.

Hecht JR et al. Interim results from PACCE: Irinotecan (Iri)/bevacizumab (bev) ± panitumumab (pmab) as first-line treatment (tx) for metastatic colorectal cancer (mCRC). Gastrointestinal Cancers Symposium 2008b;Abstract 279.

Lièvre A et al. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol 2008;26(3):374-9. Abstract

Meyerhardt JA et al. Association of dietary patterns with cancer recurrence and survival in patients with Stage III colon cancer. JAMA 2007;298(7):754-64. Abstract

Meyerhardt JA et al. Impact of physical activity on cancer recurrence and survival in patients with stage III colon cancer: Findings from CALGB 89803. J Clin Oncol 2006;24(22):3535-41. Abstract

Phillip PA et al. Phase III study of gemcitabine [G] plus cetuximab [C] versus gemcitabine in patients [pts] with locally advanced or metastatic pancreatic adenocarcinoma [PC]: SWOG S0205 study. Proc ASCO 2007;Abstract LBA4509.